Skye Bioscience Achieves Nasdaq Uplisting and Clinical Milestone
Skye Bioscience announces uplisting to Nasdaq and completion of Phase 2 clinical milestone, reflecting progress in ocular disease therapies.
The uplisting of Skye Bioscience's common stock to the Nasdaq exchange and the successful completion of dosing 56 patients with SBI-100 OE in its Phase 2a study mark significant milestones, signaling progress in the development of innovative therapies for ocular diseases. This achievement also reflects the company's commitment to enhancing visibility and unlocking value for shareholders as it advances in its clinical programs.
